Faculty

Needs Statement

Current primary care practice sites are ripe with patients who may need naloxone as a reversal agent to be used in the event of an opioid overdose or emergency.

Primary care providers need additional education and information on how to adequately speak with their patients about the use of naloxone for opioid overdose or emergencies.

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, you will be able to:

1. Describe what naloxone is in basic terms to your patients.
2. Explain naloxone’s basic use and place in therapy for patients.
3. Discuss with patients the three broad steps of opioid overdose response with naloxone.
4. Discuss how to obtain naloxone and some general regulations for access with patients.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0421-H.75-UK5C

ACGME Competencies

• Patient care
• Medical knowledge
• Practice-based learning and improvement
• Interpersonal and communication skills
• Professionalism
• Systems-based practice

CPE
This knowledge-based activity will award 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

KBSW
This activity has been approved by the Kentucky Board of Social Work for 0.75 hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

The activity is supported by Anthem.